Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
Cellcolabs’ stem cell manufacturing is based on more than 20 years of research and clinical experience led by Professor Katarina Le Blanc at the Karolinska Institute.
“We are happy to expand our offering of MSC and MSC-derivatives globally and exclusively in Japan both for research as well as clinical applications. Our partnership does not only encompass distributorship, but it will also allow REPROCELL to process, manufacture, and market further products using Cellcolabs high-quality MSCs. We are happy to address increasing requirements for MSCs in research but specifically for therapeutic applications” said Chikafumi Yokoyama Ph.D., CEO of REPROCELL Inc.
“We are happy to collaborate with REPROCELL Inc., extending the worldwide distribution of our MSCs and derivatives. Partnering with REPROCELL is in line with our mission to make MSCs for research and clinical use more available.” said Mattias Bernow MD, CEO of Cellcolabs AB.
Comments